Paediatric medicines development for Duchenne muscular dystrophy: An EU regulatory perspective.
Saved in:
| Title: | Paediatric medicines development for Duchenne muscular dystrophy: An EU regulatory perspective. |
|---|---|
| Authors: | Benchetrit S; Department of Europe and Innovation, Agence nationale de sécurité du médicament et des produits de santé (ANSM), Saint-Denis, France., Chu C; Department of Europe and Innovation, Agence nationale de sécurité du médicament et des produits de santé (ANSM), Saint-Denis, France., Athanasiou D; World Duchenne Organization, Veenendaal, The Netherlands., Scherer S; Paediatric and Orphan Medicinal Products Unit, Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany., de Andres Trelles F; Departamento de Farmacología y Toxicología, Universidad Complutense, Madrid, Spain., Stoyanova-Beninska V; European Medicines Agency (EMA), Amsterdam, The Netherlands., Martinez-Lapiscina EH; European Medicines Agency (EMA), Amsterdam, The Netherlands., De Lisa R; European Medicines Agency (EMA), Amsterdam, The Netherlands. |
| Source: | Journal of neuromuscular diseases [J Neuromuscul Dis] 2026 May; Vol. 13 (3), pp. 405-419. Date of Electronic Publication: 2025 Nov 18. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: IOS Press Country of Publication: United States NLM ID: 101649948 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2214-3602 (Electronic) Linking ISSN: 22143599 NLM ISO Abbreviation: J Neuromuscul Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2214-3602 |
|---|---|
| DOI: | 10.1177/22143602251397736 |
